137 related articles for article (PubMed ID: 23171339)
21. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
Ansari M; Krajinovic M
Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children.
Wall AM; Rubnitz JE
Pharmacogenomics J; 2003; 3(3):128-35. PubMed ID: 12815362
[No Abstract] [Full Text] [Related]
23. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Cunningham L; Aplenc R
Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
[TBL] [Abstract][Full Text] [Related]
24. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease.
Lock RB; Liem NL; Papa RA
Methods Mol Med; 2005; 111():323-34. PubMed ID: 15911988
[TBL] [Abstract][Full Text] [Related]
25. Subcutenous xenografts of human T-lineage acute lymphoblastic leukemia Jurkat cells in nude mice.
Mezencev R; McDonald JF
In Vivo; 2011; 25(4):603-7. PubMed ID: 21709003
[TBL] [Abstract][Full Text] [Related]
26. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
Liem NL; Papa RA; Milross CG; Schmid MA; Tajbakhsh M; Choi S; Ramirez CD; Rice AM; Haber M; Norris MD; MacKenzie KL; Lock RB
Blood; 2004 May; 103(10):3905-14. PubMed ID: 14764536
[TBL] [Abstract][Full Text] [Related]
27. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
Dialynas DP; Shao L; Billman GF; Yu J
Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
[TBL] [Abstract][Full Text] [Related]
28. [Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia].
Xu B; Wang BJ; Li AM; Lock R
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):151-4. PubMed ID: 16613713
[TBL] [Abstract][Full Text] [Related]
29. Biology of childhood acute lymphoblastic leukemia.
Lo Nigro L
J Pediatr Hematol Oncol; 2013 May; 35(4):245-52. PubMed ID: 23612374
[TBL] [Abstract][Full Text] [Related]
30. Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications.
Flavell DJ
Hematol Oncol; 1996 Jun; 14(2):67-82. PubMed ID: 8876636
[No Abstract] [Full Text] [Related]
31. Xenograft models for the preclinical evaluation of new therapies in acute leukemia.
Lee EM; Bachmann PS; Lock RB
Leuk Lymphoma; 2007 Apr; 48(4):659-68. PubMed ID: 17454623
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.
Ohyashiki K; Fujieda H; Miyauchi J; Ohyashiki JH; Tauchi T; Saito M; Nakazawa S; Abe K; Yamamoto K; Clark SC
Leukemia; 1991 Apr; 5(4):322-31. PubMed ID: 2027299
[TBL] [Abstract][Full Text] [Related]
33. Genetic alterations targeting lymphoid development in acute lymphoblastic leukemia.
Collins-Underwood JR; Mullighan CG
Curr Top Dev Biol; 2011; 94():171-96. PubMed ID: 21295687
[TBL] [Abstract][Full Text] [Related]
34. Growth of primary human acute leukemia in severe combined immunodeficient mice.
De Lord C; Clutterbuck R; Titley J; Ormerod M; Gordon-Smith T; Millar J; Powles R
Exp Hematol; 1991 Oct; 19(9):991-3. PubMed ID: 1893976
[TBL] [Abstract][Full Text] [Related]
35. Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.
Yang JJ; Bhojwani D
Methods Mol Biol; 2013; 999():273-84. PubMed ID: 23666706
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
37. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
[TBL] [Abstract][Full Text] [Related]
38. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.
Relling MV; Ramsey LB
Hematology Am Soc Hematol Educ Program; 2013; 2013():126-30. PubMed ID: 24319173
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of pediatric acute lymphoblastic leukemia.
Meeker ND; Yang JJ; Schiffman JD
Expert Opin Pharmacother; 2010 Jul; 11(10):1621-32. PubMed ID: 20429672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
